Sponsored Links
| CEL-SCI Commences Phase III Clinical Trial In Head And Neck Cancer In Canada |
 |
 |
 |
| Medical News - Ear, Nose and Throat | |||
|
CEL-SCI Corporation (NYSE AMEX: CVM) announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, in Canada at St. Joseph's Healthcare - Hamilton (Division of St. Joseph's Health System) in Hamilton, Ontario. The study is already ongoing at several clinical sites in the United States, Poland and India... Read more: Ear, Nose and Throat News From Medical News Today
|